TNFRSF17 and neoplasm: This example suggests that the use of sBCMA to predict loss of TNFRSF17 may be insufficient in isolation and needs to be integrated with other factors, including radiologically assessed tumor burden, as we have previously shown.26 Subclonal BCMA losses were detected using single-cell WGS in one patient previously exposed to Belantamab, and using bulk WGS in another not exposed to any anti-BCMA therapy.13 As expected, patients with clonal biallelic loss of TNFRSF17 before anti-BCMA CART/TCE treatment were characterized by primary refractoriness and poor outcomes.